Using CRISPR-Cas systems as antimicrobials - Institut Pasteur Access content directly
Journal Articles Current Opinion in Microbiology Year : 2017

Using CRISPR-Cas systems as antimicrobials

Abstract

Although CRISPR-Cas systems naturally evolved to provide adaptive immunity in bacteria and archaea, Cas nucleases can be co-opted to target chromosomal sequences rather than invasive genetic elements. Although genome editing is the primary outcome of self-targeting using CRISPR-based technologies in eukaryotes, self-targeting by CRISPR is typically lethal in bacteria. Here, we discuss how DNA damage introduced by Cas nucleases in bacteria can efficiently and specifically lead to plasmid curing or drive cell death. Specifically, we discuss how various CRISPR-Cas systems can be engineered and delivered using phages or phagemids as vectors. These principles establish CRISPR-Cas systems as potent and programmable antimicrobials, and open new avenues for the development of CRISPR-based tools for selective removal of bacterial pathogens and precise microbiome composition alteration.

Domains

Bacteriology
Fichier principal
Vignette du fichier
version_final_depot_archive.pdf (796.46 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Loading...

Dates and versions

pasteur-01911231 , version 1 (02-11-2018)

Identifiers

Cite

David Bikard, Rodolphe Barrangou. Using CRISPR-Cas systems as antimicrobials. Current Opinion in Microbiology, 2017, 37, pp.155 - 160. ⟨10.1016/j.mib.2017.08.005⟩. ⟨pasteur-01911231⟩

Collections

PASTEUR ANR
661 View
5122 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More